GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seres Therapeutics Inc (NAS:MCRB) » Definitions » Cyclically Adjusted FCF per Share

Seres Therapeutics (Seres Therapeutics) Cyclically Adjusted FCF per Share : $-1.36 (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Seres Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Seres Therapeutics's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.372. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.36 for the trailing ten years ended in Dec. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-04-28), Seres Therapeutics's current stock price is $0.825. Seres Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-1.36. Seres Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Seres Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Seres Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seres Therapeutics Cyclically Adjusted FCF per Share Chart

Seres Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -1.36

Seres Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -1.34 -1.36 -1.36

Competitive Comparison of Seres Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Seres Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seres Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seres Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Seres Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Seres Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Seres Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.372/129.4194*129.4194
=-0.372

Current CPI (Dec. 2023) = 129.4194.

Seres Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -0.050 99.695 -0.065
201406 -0.078 100.560 -0.100
201409 -0.103 100.428 -0.133
201412 -0.151 99.070 -0.197
201503 -0.233 99.621 -0.303
201506 -1.284 100.684 -1.650
201509 -0.327 100.392 -0.422
201512 -0.328 99.792 -0.425
201603 2.501 100.470 3.222
201606 -0.805 101.688 -1.025
201609 -0.428 101.861 -0.544
201612 -0.656 101.863 -0.833
201703 -0.691 102.862 -0.869
201706 -0.667 103.349 -0.835
201709 -0.101 104.136 -0.126
201712 -0.525 104.011 -0.653
201803 -0.682 105.290 -0.838
201806 -0.649 106.317 -0.790
201809 -0.577 106.507 -0.701
201812 0.315 105.998 0.385
201903 -0.797 107.251 -0.962
201906 -0.269 108.070 -0.322
201909 -0.263 108.329 -0.314
201912 -0.203 108.420 -0.242
202003 -0.343 108.902 -0.408
202006 -0.352 108.767 -0.419
202009 -0.310 109.815 -0.365
202012 -0.199 109.897 -0.234
202103 -0.337 111.754 -0.390
202106 -0.461 114.631 -0.520
202109 1.302 115.734 1.456
202112 -0.582 117.630 -0.640
202203 -0.753 121.301 -0.803
202206 -0.564 125.017 -0.584
202209 -0.496 125.227 -0.513
202212 -0.450 125.222 -0.465
202303 -0.641 127.348 -0.651
202306 0.499 128.729 0.502
202309 -0.476 129.860 -0.474
202312 -0.372 129.419 -0.372

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Seres Therapeutics  (NAS:MCRB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Seres Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Seres Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Seres Therapeutics (Seres Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
200 Sidney Street, 4th Floor, Cambridge, MA, USA, 02139
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
Executives
Paula Cloghessy officer: See Remarks C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Matthew R. Henn officer: Chief Scientific Officer C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Eric D. Shaff officer: CFO and EVP C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Thomas Desrosier officer: See Remarks 65 HAYDEN AVENUE, LEXINGTON MA 02421
Moltke Lisa Von officer: See Remarks C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Teresa L. Young officer: See Remarks C/O SERES THERAPEUTICS, INC., SUITE 1750, HOUSTON TX 77098
David S. Ege officer: See Remarks C/O SERES THERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
David Arkowitz officer: Chief Financial Officer C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Claire Fraser director C/O BECTON, DICKINSON AND COMPANY, FRANKLIN LAKES NJ 07465
Flagship Pioneering Fund Vii General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Pioneering Fund Vii, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Nutritional Health Ltp Fund, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv General Partner Llc 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv-rx, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142